Literature DB >> 2904031

Fluconazole resistance in Candida glabrata.

D W Warnock, J Burke, N J Cope, E M Johnson, N A von Fraunhofer, E W Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2904031     DOI： 10.1016/s0140-6736(88)92919-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  51 in total

Review 1.  Critical annotations to the use of azole antifungals for plant protection.

Authors:  H Hof
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.

Authors:  P Phillips; S Shafran; G Garber; C Rotstein; F Smaill; I Fong; I Salit; M Miller; K Williams; J M Conly; J Singer; S Ioannou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

3.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

4.  Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

5.  Standardized susceptibility testing of fluconazole: an international collaborative study.

Authors:  M A Pfaller; B Dupont; G S Kobayashi; J Müller; M G Rinaldi; A Espinel-Ingroff; S Shadomy; P F Troke; T J Walsh; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

6.  Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.

Authors:  Annemarie Borst; Maria T Raimer; David W Warnock; Christine J Morrison; Beth A Arthington-Skaggs
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 8.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients.

Authors:  D Sullivan; D Bennett; M Henman; P Harwood; S Flint; F Mulcahy; D Shanley; D Coleman
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

10.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.